YOGYAKARTA, Indonesia, Aug. 24, 2026 /PRNewswire/ — Malaysia Healthcare Travel Council (MHTC) once again strengthened Malaysia’s presence in Indonesia through MHX Yogyakarta 2026, held from 20 to 23 August 2026 at the Grand Atrium, Pakuwon Mall Jogja. The four-day event came on the back of a record year for the Indonesian market, which generated RM2.2 billion in healthcare travel revenue in 2025, marking a 24% year-on-year increase. The four-day healthcare consumer event underscores Malaysia Healthcare’s commitment to bringing trusted, high-quality healthcare services closer to Indonesian communities while expanding its footprint in one of Indonesia’s fastest-growing regional centres. Held under the Malaysia Year of Medical Tourism (MYMT) 2026 campaign themed Healing Meets Hospitality, MHX Yogyakarta 2026 reinforces Malaysia’s position as the preferred destination for medical tourism by combining world-class medical expertise with compassionate patient care and seamless healthcare experiences.

Yogyakarta has emerged as a strategic market for Malaysia Healthcare, supported by a well-educated population, increasing demand for advanced specialty care, and convenient direct connectivity to Kuala Lumpur. These factors present strong opportunities to further strengthen healthcare collaboration between Malaysia and Indonesia and to provide greater access to specialised treatment options for Indonesian patients.

Speaking on the occasion, Rahmatullah Baragau, MHTC’s Head of Indonesia Market said: “Indonesia has always been Malaysia Healthcare’s closest and most valued market, and Yogyakarta represents an exciting opportunity as healthcare awareness and demand for specialised treatments continue to grow. Through MHX Yogyakarta 2026, we aim to strengthen public confidence in Malaysia Healthcare while bringing our trusted healthcare ecosystem closer to local communities.”

More than 15 member hospitals participated, showcasing Malaysia’s strengths across various medical disciplines including cardiology, oncology, orthopaedics, fertility, health screening, gastroenterology, and other specialised services.

Participating list of hospitals:

1. Island Hospital Penang
2. Institut Jantung Negara
3. Mahkota Medical Centre
4. Subang Jaya Medical Centre
5. Alpha IVF & Women’s Specialists
6. Ampang Puteri Specialist Hospital
7. GenPrime Everlink Fertility Centre
8. Hospital Picaso
9. Damansara Specialist Hospital 2
10. KPJ Klang Specialist Hospital
11. MSU Medical Centre
12. Optimax Eye Specialist Centre
13. Pantai Hospital Kuala Lumpur
14. Pantai Hospital Penang
15. Penang Adventist Hospital
16. Sunway Medical Centre Damansara
17. Sunway Medical Centre Penang
18. Sunway Medical Centre Sunway City Kuala Lumpur
19. Thomson Hospital Kota Damansara

Indonesia continues to be Malaysia Healthcare’s largest source market. Healthcare traveller arrivals from Indonesia reached 968,000 in 2025, a 16% increase from the previous year, reflecting sustained confidence among Indonesian patients in Malaysia’s healthcare offerings. MHX Yogyakarta 2026 forms part of MHTC’s broader strategy to strengthen long-term partnerships with communities, healthcare stakeholders, and local organisations across Indonesia, while supporting MYMT 2026’s goals to position Malaysia as the world’s preferred medical tourism destination.

For media inquiries and further information, please contact:

Mohamad Shahizam Fauzi
Head, Communications
+603 8776 6168
shahizam.f@mhtc.org.my

Siti Hamidah Mohd Najib
Senior Executive, Communications
+603 8776 6168
hamidah.m@mhtc.org.my

About Malaysia Healthcare Travel Council

Malaysia Healthcare Travel Council (MHTC), established in 2009 under the purview of the Ministry of Health (MOH) Malaysia, is entrusted with developing and nurturing the “Malaysia Healthcare” brand. MHTC enhances, coordinates, and promotes Malaysia’s healthcare travel industry by fostering industry collaborations and building valuable public-private partnerships both domestically and internationally. With 91 member hospitals nationwide, MHTC continues to elevate the healthcare travel ecosystem through strong branding, seamless patient experiences, and strategic market initiatives. In line with these efforts, MHTC is spearheading the Malaysia Year of Medical Tourism (MYMT) 2026, the nation’s first dedicated year to celebrate and advance healthcare travel. MYMT 2026 serves as a milestone initiative to showcase Malaysia’s world-class healthcare offerings, strengthen its position as the premier global healthcare destination, and highlight the industry’s significant contribution to the national economy.

MHTC’s website: https://www.malaysiahealthcare.org.

MACAU, Aug. 24, 2026 /PRNewswire/ — World Youth Forum (WYF), an international nonprofit platform engaging 500,000+ young people annually across 30+ countries through education, competitions, conferences and youth-led initiatives, concluded WYF-FLALS 2026 in Macao, bringing together 400+ students for five days of interdisciplinary learning and cross-cultural collaboration at the Future Liberal Arts Leadership Summit.

Participants came from more than 10 countries and regions, including Cambodia; China, including Hong Kong SAR, Macao SAR and Taiwan region; India; Indonesia; Singapore; Thailand; the United States; and Vietnam (listed in alphabetical order). Following WYF-FELS in Hong Kong, WYF-FLALS concluded the 2026 summit series, bringing together more than 1,000 young people through economics, liberal arts and cross-cultural exchange.

Jointly initiated by WYF and the Organizing Committee of International Academic Decathlon (IAD), WYF-FLALS explored Our Changing Climate through social science, literature, fine arts, science, mathematics, economics and music. Through interdisciplinary challenges, projects, speeches and exchanges, students examined the scientific, economic, social and cultural dimensions of climate change.

Guests included Wong Yee Lam, Member of the Administrative Committee, Commerce and Investment Promotion Institute, Cheng Wai Tong, Deputy Director, Macao Government Tourism Office, Cheong Man Fai, Head of the Department of Youth Affairs, Education and Youth Development Bureau, Li Feilong, Director of the Taiwan Affairs Department, Liaison Office of the Central People’s Government in the Macao SAR, Jia Qiong, Second Secretary, Department of Information and Public Diplomacy, Office of the Commissioner of the Ministry of Foreign Affairs of the People’s Republic of China in the Macao SAR, Lao Ngai Leong, Deputy to the National People’s Congress, Si Ka Lon, Deputy to the National People’s Congress, Wong Kit Cheng, Vice-Chairperson of the All-China Youth Federation, Lam Ieng Pui, Founding President, Chinese Youth Advancement Association, Zhang Senhua, President, Chinese Youth Advancement Association, Zhao Gang, Director-General, Global Innovation Center, Amy Dosch, Executive Director, United States Academic Decathlon (USAD), Henry Peng, Global Council Member, World Youth Forum (WYF). Through academic sessions and exchanges with students, they connected classroom knowledge with global challenges and encouraged participants to approach complex issues from multiple perspectives.

Highlights included the Super Quiz, Academic Exploration Fair, Team Spark & Global Fusion Fest, U20–Master Call, U20–Idea Incubation, Themed Speech, U20–Youth Voice and Bridging Worlds: Real-World Learning Journey. Awards recognized excellence in academics, teamwork, communication and creativity.

WYF will continue working with IAD, schools, educators and international partners to expand access to interdisciplinary, challenge-based learning.

• HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity
• Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales

SEOUL, South Korea, Aug. 24, 2026 /PRNewswire/ — Hanmi Pharm announced today that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group, for the development, manufacturing, and commercialization of Hanmi’s novel metabolic treatment candidate, HM17321 (UCN2), for obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, worldwide. The agreement excludes South Korea.

HM17321 is a proprietary UCN2 (urocortin-2) analog with a non-incretin mechanism of action and represents a potential first-in-class treatment designed to simultaneously promote weight loss and preserve lean body mass. In contrast, while existing GLP-1 based incretin therapies have demonstrated meaningful weight reduction, these therapies are associated with a reduction in lean body mass.

In preclinical studies, HM17321 has shown both quantitative and qualitative improvements in weight reduction when used as a monotherapy and in combination with GLP-1-based therapies. Furthermore, as a peptide-based therapeutic, HM17321 may have future potential for use in fixed-dose combination (FDC) products or combination regimens with incretin-based treatments.

In November 2025, Hanmi received IND (Investigational New Drug) clearance from the U.S. FDA (Food and Drug Administration) to initiate a Phase 1 clinical trial of HM17321. The ongoing clinical study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 in healthy volunteers and individuals with obesity.

Hanmi will be responsible for completing the Phase 1 clinical trial, after which Genentech will take over development starting with Phase 2 clinical trials.

In-Young Choi, Senior Executive Vice President, Head of R&D Division of Hanmi Pharm stated, “The paradigm of obesity treatment is evolving beyond simple weight reduction toward improving body composition and restoring metabolic health. We are very pleased that the differentiated scientific mechanism and development potential of HM17321 have been recognized by the global market. Hanmi Pharm will continue to dedicate its efforts to developing innovative medicines that can deliver more fundamental and differentiated therapeutic value to patients.”

“With our growing cardiometabolic pipeline and strong diagnostic expertise, Roche is advancing a portfolio designed to meet the diverse needs of people living with obesity and related health conditions,” said Boris L. Zaïtra, head of Roche Corporate Business Development. “By licensing this next-generation investigational therapy with first-in-class potential from Hanmi, Roche and Genentech will pursue a differentiated approach to selectively reduce fat mass while improving both muscle mass and muscle function. We look forward to further developing this medicine in order to address important unmet needs for people living with obesity and other metabolic diseases.”

Under the terms of the agreement, Hanmi will receive an upfront payment of USD 190 million from Genentech. Including development, regulatory, and commercial milestone payments, the total deal value could reach approximately USD 2.3 billion. In addition, Hanmi will be eligible to receive tiered royalties on future product sales following commercialization.

• AI use among surveyed sports fans increased in 2026, with accuracy driving fan trust
• Nearly half of respondents would download a single, consolidated sports app — but only about 3 in 10 would pay for one
• Managing multiple subscriptions has become a source of frustration for surveyed sports fans

ARMONK, N.Y., Aug. 24, 2026 /PRNewswire/ — New research commissioned by IBM (NYSE: IBM) reveals the digital expectations of surveyed sports fans are rising as they navigate more platforms, subscriptions and technology.

According to the latest IBM Sports Intelligence Report*, based on responses from more than 20,000 sports fans across 12 countries, 46% of those surveyed say their expectations for digital sports experiences are higher than they were one to two years ago. That shift is already visible in their viewing habits. Thirty percent (30%) of surveyed fans say they are most likely to use a subscription streaming service to watch live sports, nearly even with the 29% who select linear broadcast. Respondents who watch sports through digital platforms – such as streaming services — cite convenience (43%) and access to exclusive content (27%) as the top reasons for choosing digital viewing over linear.

AI usage gains momentum, as accuracy shapes the AI-powered sports experience
AI use among all respondents increased from 52% to 69% year over year, while 59% say they trust AI-generated sports content — down from 63% last year. As AI becomes more widely utilized, the data suggest that familiarity may be a factor in driving trust: surveyed fans who already use AI trust AI-generated sports content nearly three times more than those who do not (74% vs. 27%). According to the research, accuracy matters more to fans than speed: 44% of respondents prioritize highly accurate sports information compared with 23% who prioritize speed, while accuracy is the top driver of trust in AI-powered insights, cited by 45%.

Sports apps emerge as a central hub for fandom
Nearly three-quarters (72%) of surveyed fans report using sports apps. A similar share (74%) say they trust sports apps and digital platforms to provide accurate and reliable information, second only to traditional broadcasters at 79%. Many are also seeking a more consolidated experience. While 47% of respondents say they would be likely to download and use a centralized sports app, only 29% are willing to subscribe and pay for one. Premium live viewing and having all content in one place are top potential drivers of paid sports app subscriptions at 61% each, followed closely by exclusive content and an ad-free experience, both at 58%. 

Among surveyed sports app users, 40% cite having information in one place as the leading motivator for using sports apps, while 35% use them for real-time updates when unable to watch or listen to an event. In addition, 30% of these respondents say they use live statistics and analytics more than they did one to two years ago, making it the fastest-growing app feature measured. Apps also extend beyond information and engagement to transactions. In the past year, 33% of surveyed users bought tickets, 30% ordered food or beverages at a live event, and 29% purchased merchandise through a sports app.

“Sports fans want reliable, connected digital experiences that bring everything together in one place so they don’t need to toggle back and forth between multiple apps,” said Kameryn Stanhouse, Vice President, Sports and Entertainment Partnerships, IBM. “As fans’ digital expectations keep growing, the organizations that earn their trust will be the ones that combine accuracy with streamlined experiences that put the power in fans’ hands.”

Other key findings:

• More platform choices add complexity for fans: 39% of surveyed fans report frustration with managing multiple subscriptions to watch sporting events they care about, rising to 46% among Gen Z respondents.
• Fans expect their viewing habits to evolve: 75% of respondents believe their sports viewing habits will change in the next two to three years, including 89% of Gen Z and 84% of Millennial fans. More than one-third (36%) of all surveyed fans expect to watch more live broadcast or streaming events.
• Sports creators influence fans well beyond the game: Nearly half (49%) of surveyed fans follow sports creators, increasing to about 6 in 10 among Gen Z and Millennial fans. Their reach extends past sports, with 70% of surveyed followers confirming creators shape their opinions or awareness in areas such as fashion, music or technology, including 22% who say creators influence multiple aspects of their lifestyle.

To view the full study, visit: https://newsroom.ibm.com/image/IBM+Sports+Intelligence+Report+August+2026.pdf 

*Study Methodology
This survey was commissioned by IBM and conducted by Morning Consult in June 2026 among a total sample of 20,589 sports fans ages 18 and older in the US, Canada, the UK, France, Germany, Italy, Spain, India, the UAE, Saudi Arabia, Mexico and Brazil. The interviews for each country were conducted online, and the data is unweighted, with ~2,000 responses per market in the US, Canada, the UK, France, Germany, Italy, Spain, and India and ~1,000 responses per market in the UAE, Saudi Arabia, Mexico and Brazil.

To qualify for this survey, respondents must be at least an average sports fan and follow one or more of the following sports: soccer, cricket, tennis, basketball, baseball, rugby, golf, American football, F1 racing, track and field, swimming, and the Olympics.

About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media contact:

Marisa Conway
IBM Corporate Communications
conwaym@us.ibm.com